by Dr. Ed Weber | Jul 27, 2021 | PCa Commentary, Uncategorized
Hot flashes are an especially unpleasant adverse effect of androgen deprivation therapy (ADT). They occur with varying intensity in about 70% of men undergoing treatment. Hot flashes (also termed hot flushes) are experienced as a feeling of increased of body heat...
by Dr. Ed Weber | Jun 30, 2021 | PCa Commentary
Neuroendocrine Prostate Cancer: What is it? Under the sustained and intense suppression of testosterone with Lupron or Degarelix – and now with the even stronger suppression with drugs like Xtandi and Zytiga, prostatic adenocarcinoma may undergo a...
by Dr. Ed Weber | May 28, 2021 | PCa Commentary
Radioligand Therapy (RLT) targeted with the radionuclide Lutetium 177 or Actinium 225 has been found in early studies to be promising, safe and effective. A Gestault of results has generally shown about a 50% PSA decline in 50% of patients and a median...
by Dr. Ed Weber | Apr 13, 2021 | PCa Commentary
Genomic classifier panels for risk stratification and whole-genome sequencing in search of actionable mutations both provide personal molecular data that can guide management decisions. However, each provides an entirely different category of information. Both are...
by Dr. Ed Weber | Mar 25, 2021 | PCa Commentary
Metastases Directed Therapy (MDT) has become a realistic option for men who develop metastases after primary therapy. The theoretical foundation of MDT was succinctly stated by David Palma, M.D., PhD: “The oligometastatic paradigm hypothesizes that...
by Dr. Ed Weber | Feb 25, 2021 | PCa Commentary
A Commentary discussing bone health and bone protective therapy may not be as eye-catching as new developments in PSMA and Axumin imaging or radioligand therapy with Lu-177, but as the old spiritual says: “dem bones, dem bones gonna walk around …” and we...
